<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR69">
 <label>69.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Oâ€™Brien</surname>
    <given-names>KL</given-names>
   </name>
   <name>
    <surname>Chandran</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Weatherholtz</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Jafri</surname>
    <given-names>HS</given-names>
   </name>
   <name>
    <surname>Griffin</surname>
    <given-names>MP</given-names>
   </name>
   <name>
    <surname>Bellamy</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Millar</surname>
    <given-names>EV</given-names>
   </name>
   <name>
    <surname>Jensen</surname>
    <given-names>KM</given-names>
   </name>
   <name>
    <surname>Harris</surname>
    <given-names>BS</given-names>
   </name>
   <name>
    <surname>Reid</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Moulton</surname>
    <given-names>LH</given-names>
   </name>
   <name>
    <surname>Losonsky</surname>
    <given-names>GA</given-names>
   </name>
   <name>
    <surname>Karron</surname>
    <given-names>RA</given-names>
   </name>
   <name>
    <surname>Santosham</surname>
    <given-names>M</given-names>
   </name>
   <collab>Respiratory Syncytial Virus Prevention study g</collab>
  </person-group>
  <article-title>Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial</article-title>
  <source>Lancet Infect Dis</source>
  <year>2015</year>
  <volume>15</volume>
  <issue>12</issue>
  <fpage>1398</fpage>
  <lpage>1408</lpage>
  <pub-id pub-id-type="doi">10.1016/S1473-3099(15)00247-9</pub-id>
  <?supplied-pmid 26511956?>
  <pub-id pub-id-type="pmid">26511956</pub-id>
 </element-citation>
</ref>
